the native lung of four SLT recipients. Twenty pa tients survived (DLT=17, SLT=3) and 11 died (DLT=4, S L T -7) of disseminated aspergillosis (SLT-2), pulmo nary invasive disease (DLT=1), bronchiolitis obliter ans (DLT=2, SLT=2, CMV pneumonitis (SLT=1), dif fuse alveolar damage (SLT=2), and hyperacute rejection (DLT=1). Complicated infection and mortal ity were more common in SLTs than DLTs CP<0.05). We conclude that infection with Aspergillus is not in frequent in the lung transplantation population. Sin gle lung recipients develop more complicated infec tion than double lung recipients after Aspergillus infection, with native lung being a potential source of infection.
With the increased survival of lung transplant recipients (1) we are beginning to recognize previously unreported prob lems with long-term immunosuppression. The lung trans plant patient is at risk for opportunistic infection, whichalong with chronic rejection, termed "bronchiolitis obliterans" (BO)-* is a major cause of morbidity in long-term survivors. Bacterial infection represents about 65% of infection-however, viral and fungal infections appear to have proportionately higher mortality (2) .
Fungal infections with Aspergillus species are a particular threat to the transplanted lung since these organisms are ubiquitous, can easily gain entrance into the airways, and are difficult to treat effectively.
In lung transplant literature, isolated reports of Aspergil lus infections suggest that aspergilloma, necrotizing tracheo bronchitis, pulmonary invasive, and disseminated aspergil losis are significant causes of morbidity (3, 4) .
To assess the impact of Aspergillus infection on a lung transplant population, we reviewed data from 141 lung al lograft recipients who were transplanted over a nine-year period and documented the incidence, clinical manifesta tions, and morbidity of Aspergillus infections.
METHODS

Patient population.
Between November 1983 and May 1993, 141 patients received lung transplants at the Toronto Hospital. Of these, 93 received double lung (DLT) and 48 received single (SLT) lung transplants.
Nine patients underwent a second transplant procedure. The in dications for the transplant included septic lung disease (cystic fi brosis, bronchiectasis) in 36 patients; obstructive lung disease (em physema, alpha-l-antitrypsin deficiency) in 49 patients; restrictive lung disease (idiopathic pulmonary fibrosis) in 28 patients, and pul monary vascular disease (primary pulmonary hypertension, Eisenmenger's syndrome) in 13 patients; other causes of end-stage lung diseases included bronchiolitis obliterans (4), eosinophilic granuloma (5), sarcoidosis (2), lymphangioleiomyomatosis (1), mediastinal gran uloma (2), sclerodema (2 ), bronchiolitis obliterans organizing pneu monia (1).
Mean age was 40±12 in DLT patients and 47±10 years in SLT patients. As of December 1993, 69/93 DLT and 21/48 SLT patients were alive. All mycology reports and autopsy reports were reviewed for evidence of positive Aspergillus cultures in bronchoalveolar la vage (BAL) fluid, sputum, or other available body fluid.
Definitions. Aspergillus infection was categorized as either colo nization or complicated infection. Colonization was defined as posi tive BAL or sputum cultures for Aspergillus without clinical signs of illness. Complicated infections included the following: (1) Aspergillus bronchitis was diagnosed as the development of purulent sputum positive for Aspergillus and negative for bacterial species; (2) as pergilloma was diagnosed by finding a characteristic mycetoma on chest radiograph and CT scan in the presence of positive BAL or sputum cultures; (3) pulmonary invasive aspergillosis was diagnosed by findings of chest radiograph infiltrates and pathological evidence of Aspergillus organisms invading lung parenchyma; (4) dissemi nated aspergillosis was diagnosed when Aspergillus organisms were cultured or seen pathologically at sites distant from the lung.
Immunosuppression. From December 1992 to November 1993 in duction immunosuppression consisted of triple therapy with Minne sota antilymphocyte globulin (MALG), cyclosporine, and azathioprine. From January 1993 to May 1993 patients were randomized in a blinded fashion to receive an i.v. antilymphocyte preparation (ALP) serum or placebo for seven days posttransplant in an attempt to determine the effect of ALP therapy on graft rejection episodes. * Abbreviations: ALP, antilymphocyte preparation; ATD, alpha-lantitrypsin deficiency; BAL, bronchoalveolar lavage; BO, bronchioli tis obliterans; CF, cystic fibrosis; CMV, cytomegalovirus; DLT, dou ble lung transplant; MALG, Minnesota antilymphocyte globulin; SLT, single lung transplant; SSLT, sequential single lung trans plant; TBB, transbronchial biopsy.
Fourteen of the patients included in this report were participants in this study.
Steroids were started two weeks after transplant. MALG was started as a continuous infusion at 10-20 mg/kg/day immediately after transplant, with the dosage adjusted to achieve a lymphocyte count o f 0.15-0 .3 0 X 1003/ml. MALG was discontinued after 5-7 days when adequate cyclosporine levels were obtained.
Cyclosporine was given perioperatively at 1.5-3.0 m gkg/day by continuous infusion with conversion to the oral preparation at 5-10 mg/kg/day when gastrointestinal function resumed. The dose was then adjusted to obtain a whole-blood level of 250-300 ng/ml in the first year and then 150-200 ng/ml thereafter. Cyclosporine was measured by radioimmunoassay technique using a monoclonal anti body to cyclosporine.
Azathioprine was given as an initial i.v. dose of 1.5 mg/kg/day; then orally over nine months and tapered to 0.5-1.5 mg/kg/day thereafter.
Since 1990, triple therapy has remained similar to the above, with the addition of methylprednisolone given intraoperatively at graft perfusion at a dose o f 500 mg i.v. Maintenance steroids are continued with prednisone at 0.5 mg/kg/day tapering to 0.25 mg/kg/day over the first 6 -9 months, then to 15 mg every other day after one year.
Infection prophylaxis. Bacterial: Since 1983, prophylactic broad spectrum antibiotics were used perioperatively for 3-5 days in all graft recipients. If specific organisms were isolated from donor re cipient tracheal specimens, antibiotics were tailored to organism sensitivities. In May 1990, a standard prophylactic antibiotic regi men was instituted using ceftazidime pentahydrate (1 g/8 hr i.v.) and Clindamycin (600 mg/6 hr i.v.) for 2-3 days posttansplant. Cystic fibrosis (CF) patients were given a seven-to ten-day course of i.v. antibiotics based on sputum culture and sensitivities of their preop erative colonizing organisms along with aerosolized tobramycin for ten days posttransplant.
Viral: Since 1989, CMV prophylaxis using hyperimmune globulin with or without an antiviral agent has been used when positive serology is present in the donor recipient. Since 1991, CMV hyper immune globulin has been given at 150 mg/kg within the first 48 hr posttransplant, then again in two weeks. Subsequent doses at 100 mg/kg are then given once a week at 4, 6, 8, 10, 12, and 16 weeks posttransplant. Ganciclovir at 5 mg/kg b.i.d. for 14 days, then 5 mg/kg/day 3 days a week for 12 weeks is administered to the same patient groups. CMV-negative recipients receiving CMY-negative grafts receive oral acyclovir at 400 mg b.i.d. for 3 months.
Protozoal and fungal: Pneumocystis carinii prophylaxis consists of trimethoprim-sulfamethoxazole at 160/800 mg twice a day on Mon day, Wednesday, and Friday. In sulfa-allergic patients, dapsone plus trimethoprim or aerosolized pentamidine is used. Oral thrush pro phylaxis consists of nystatin slurry (100,000 units), oral swish, and swallow q.i.d. for the first 3 weeks posttransplant.
Infection and rejection surveillance. Before 1988, posttransplant bronchoscopies with transbronchial biopsies (TBB) and bronchoal veolar lavage (BAL) were performed twice during the first three months, once every three months for the first year, every six months during the second year, and then yearly. Additional bronchoscopies were done when clinically warranted. In 1988 surveillance TBB and BAL were done 3 and 6 weeks after transplant, every three months the first year, every six months the second year, and then at least yearly. Since July 1990, routine surveillance bronchoscopies have been done at 1, 3, and 6 weeks; 3, 6, 9, 12, 18, and 24 months; and then yearly posttransplant. BAL fluid is cultured for bacterial, viral, fungal and mycobacterial organisms and appropriate treatment is given. Since 1990, a standardized pathological grading system of TBB tissue for acute and chronic rejection has been used (5). Acute rejection is treated with an i.v. bolus of methylprednisolone at 1 g/day for 3 days, then prednisone is continued from 40 mg/day and tapered over three weeks back to the previous maintenance dosage.
Treatment. Patients with Aspergillus colonization received either itraconazole at 200 mg/day for one month or ketoconazole at the a 27, 1996 jame dose. For Aspergillus bronchitis, itraconazole was increased to 400 mg/day and aerosolized amphotericin B added. For other com plicated Aspergillus infections, i.v. amphotericin B was given. After a 1 mg test dose daily, dosage proceeded with 0.25 mg/kg on day 1, followed by 0.5 to 1.0 mg/kg per 24 hr. If renal function began to deteriorate, the amphotericin dosage was reduced by one half the previous dosage and cyclosporine levels kept at the lowest therapeu tic range.
Statistical analysis. Data are presented as the m ean±SD or as proportions. Comparisons between groups have been done with chisquare and expressed as relative risk. Differences were assumed to be significant when P<0.05.
RESULTS
Aspergillus infection was identified in 31/141 (22%) of the recipients transplanted between 1983 and 1993 ( Table 1) . Transplant indications included cystic fibrosis (DLT=6), bronchiectasis (DLT=1), emphysema (DLT=8), alpha-1 an titrypsin deficiency emphysema (DLT=3, SLT=2), pulmo nary fibrosis (SLT=6), primary pulmonary hypertension (SLT=1), Eisenmenger's syndrome (DLT=1), eosinophilic granuloma (DLT=1), sarcoidosis (DLT=1), and scleroderma (SLT=1).
Aspergillus isolates were initially obtained from BAL fluid in 27/31 recipients, from sputum in 3/31 recipients, and from a resected mycetoma in one recipient. Isolated species in cluded A fumigatus in 15, A niger in 2, A flauus in 1, and unidentified species in 13 patients. Only one recipient, an SLT, had pretransplant isolation of Aspergillus and that was in BAL fluid.
The times from transplant to isolation of a positive isolate were 6 ±8 and 14±16 months in DLT and SLT, respectively. The majority (23/31=74%) of positive isolates were within the first nine months posttransplant (DLT=17, SLT=6). The remaining eight recipients had positive isolates occurring from 15 to 60 months posttransplant.
The manifestations of Aspergillus infection are listed in Table 2 . Colonization alone occurred in 19/141 (13%) while complicated infection occurred in 12/141 (8%) of all trans plant recipients. However, of the 31 patients with Aspergillus infections, 12/31 (39%) developed complicated infection. The risk of developing complicated Aspergillus infection was 7/48 = 15% for SLT, and 5/93 = 5% for DLT.
This relative risk for SLT recipients versus DLT recipients developing complicated infection was 3:1 (P<0.05). Clinical correlates. Symptoms were absent in patients with colonization alone. One DLT patient with BO and sub sequent disseminated Aspergillus infection had no pulmo nary symptoms other than dyspnea, which had been previ ously attributed to his BO. The remaining patients with complicated infection had significant symptoms that in cluded purulent sputum (3 patients), respiratory distress (4 patients), and fever and malaise (5 patients). Hemoptysis occurred in the two SLT patients with aspergillomas and in one patient with disseminated disease. Five patients had some combination of the above symptoms.
Chest radiographs were negative in the patients with col onization alone (DLT=16, SLT=3) and in four patients with complicated infection that included Aspergillus bronchitis (DLT=1, SLT=1), a retroperitoneal abscess (DLT=1), and disseminated infection (DLT=1). Four SLT patients had chest radiograph abnormalities in the form of cavities and consolidation beginning in the native lung, while two SLT patients had infiltrates beginning in the transplanted lung ( Table 3 ). The DLT patient with a right empyema developed a right pneumothorax and another DLT patient with pulmo nary invasive aspergillosis had a right lower lobe cavitary lesion.
Therapy. Itraconazole alone was given to eighteen pa tients once Aspergillus was isolated (DLT=16, SLT=2). Two patients with Aspergillus colonization (DLT=1, SLT=1) re ceived no therapy and one SLT patient received ketoconazole for one month. One DLT patient with Aspergillus bronchitis was treated with itraconazole plus aerosolized amphotericin B, resulting in significant improvement in symptoms and clearing of Aspergillus from BAL fluid.
Amphotericin B therapy (with or without prior itracon azole) was instituted in eight patients (DLT=3, SLT=5). One left-SLT patient developing a right upper lobe aspergilloma underwent a successful pneumonectomy of the native lung after prior itraconazole and i.v. amphotericin B.
Recurrence of Aspergillus-positive cultures after itracon azole therapy developed in 6/16 (37.5%) DLT patients. None of the recurrences presented as complicated infection, and (Table 4) . Mortal ity was four times higher in SLT (7/10=70%) than in DLT (4/21=19%) recipients (RR=3.3 to 0.83)-however, death was attributed directly to Aspergillus in only 3 patients (SLT=2, DLT=1). Three survivors had complicated infection that included a right empyema (DLT=1), Aspergillus bron chitis (DLT=1), and an aspergilloma that was surgically removed (SLT=1). Table 5 shows the causes of death in these patients. Mean time from Aspergillus insolation to death was similar in both groups: 6.8±5 and 6.7±10 months in DLT and SLT patients, respectively. Disseminated aspergillosis to the brain, heart, thyroid, and gastric mucosa occurred in 2 SLT patients, and pulmonary invasive aspergillosis in the setting of a malig nant lymphoma occurred in 1 DLT patient.
A diagnosis of BO was made on clinical grounds (6) and/or diagnosed histologically at autopsy in 7/11 (64%) patients with Aspergillus infection who died: (DLT=3, SLT=4) and was the cause of death in four of these patients (DLT=2, SLT=2). In eight of the 20 surviving patients (40%) a diag nosis of BO was made by clinical grounds and/or found in TBB specimens.
Additional causes of death in the 11 nonsurvivors in cluded diffuse alveolar damage associated with both pul monary invasive aspergillosis and a suppurative aspergil loma (SLT=2); CMV pneumonitis (SLT=1); and hyperacute rejection during a retransplant attempt (DLT=1).
DISCUSSION
Because of poor tissue matching of many solid organ al lografts to the recipient, relatively intense immunosuppres sion with multiple agents is necessary to protect the graft from rejection. This has resulted in a variety of opportunistic infections, of which fungal infections have been particularly difficult to treat.
Aspergillus infections have been reported in renal (7), bone marrow (8), liver (9, 10) , and heart-lung recipients (4), with nearly 100% mortality in orthotopic liver transplants (10) . The lung graft is particularly at risk for Aspergillus infection since Aspergillus is a ubiquitous air-borne organism and has easy access to the respiratory tract by direct inhalation. In addition, it is likely that the normal lung antimicrobial de fense mechanisms are impaired in the lung allograft [11) further increasing its susceptibility to colonization and pos sibly dissemination.
We have found that Aspergillus infection occurred in 22% of our lung transplant recipients, with 9% developing com plicated infection. This compares with a reported incidence of 23% and morbidity of 11% in a group of 70 single lung recipients (12) . Our population comparing SLT versus DLT recipients, however, shows that a higher percentage of SLT (15%) than DLT (5%) recipients developed complicated infec tion once colonized. One report evaluating the outcome of the native lung in a group of single lung recipients, reported 7/16 developing pathology in the native lung that resulted in varying degrees of impact on the patient from mild effects to severe recurrent infections (13) . In our population, 4/10 SLT recipients (Table 3 ) appeared to have Aspergillus infection beginning in the native lung. One of these had pretransplant isolation of Aspergillus. Structural and functional abnormal ities may predispose the native immunosuppressed lung to reactivation of a preexisting infection or to easier coloniza tion with a new infection. The majority of our isolates were A fumigatus (48%) and 42% were unidentified species of Aspergillus. Half (6/12) of the complicated infections were secondary to A fumigatus. This included only one of the three pulmonary invasive in fections. Other reports have implicated this species as caus ing invasive disease in up to 76% of isolates (14) and as being associated with bronchial airway stenosis (15) . In the popu lation we describe, only one SLT recipient with an end-to-end anastomosis showed involvement of the donor bronchus with Aspergillus and the species was unidentified. The remaining nine SLTs with the same anastomosis did not show similar anastomotic problems.
A form of invasive aspergillosis called invasive ulcerative tracheobronchial aspergillosis has been described in six lung transplant recipients (14) . In these patients, fiberoptic bron choscopy revealed three morphologic forms of the disease: tracheobronchitis, ulcerative bronchitis, and pseudomembra nous bronchitis. It was suggested that these three forms represented a progressive spectrum of disease ranging from a mild bronchitis to the more widespread invasive disease.
Two of the patients in our review may have demonstrated parts of this spectrum. The first patient was a DLT recipient (SSLT telescoping anastomosis technique) who developed Aspergillus bronchitis and was treated with aerosolized ampho tericin B in addition to two months of oral itraconazole. Although tracheobronchitis was seen throughout the air ways, no ulcerations or involvement of the anastomotic su ture lines were seen. This patient responded to therapy and showed no progression of disease.
The second patient, however, was an SLT recipient (endto-end anastomosis technique) who developed infiltrates on chest radiograph in the transplanted lung. At autopsy, dif fuse alveolar damage of the right lung was found along with circumferential ulceration and local invasion of the donor mainstream bronchus with Aspergillus.
The number of patients dying directly of Aspergillus infec tion of all patients transplanted during the study period was 2% (3/140). This compares with a mortality of 4.3% in an other series of isolated SLT recipients {12). A proportionately higher number of deaths occurred in our SLT recipients compared with DLT recipients with Aspergillus infection. However, only 27% (3/11) of deaths were directly due to Aspergillus infection. The higher mortality in SLTs might reflect a limited pulmonary reserve in response to multiple pulmonary complications posttransplant.
A diagnosis of BO was made in 50% (15/31) of our AspergilZus-infected recipients and BO as a cause of death was found in 36% (4/11) of the recipients dying with Aspergillus infec tion. The incidence of BD in the overall transplant population ranges from approximately 35 to 50% (16, 17) . Thus, in this Aspergillus infected group, the finding of BO may simply represent that of the general transplant population. Further evaluation is needed to determine if there is a definite cause and effect between development of BO and Aspergillus infec tion.
The role of antifungal therapy in eradicating Aspergillus colonization and thus presumably preventing more serious infection has not yet been determined. As well, further study is required to assess whether transplant recipients with ev idence of Aspergillus in BAL fluid cultures should be evalu ated more frequently by bronchoscopy to determine if inter ventions such as aerosolized amphotericin b in addition to conventional antifungal therapy can be effective in prevent ing progression to pulmonary invasive aspergillosis. In our patients, the recurrence of Aspergillus-positive cultures after initial therapy was frequent but did not manifest as compli cated infection. The majority of these patients, however, were DLT recipients and thus lacked the unique predisposition (an abnormal native lung) that SLT recipients may have for developing complicated infection. Clearly the best way to assess the roles of both prophylaxis and close clinical surveil lance is through a prospective study.
In summary, Aspergillus infection is not infrequent in lung transplant recipients and may lead to significant morbidity. SLT recipients are at an increased risk of developing compli cated Aspergillus infection and the native, structurally ab normal lung is a potential source of infection. Although single lung transplantation is indicated for individuals with nonseptic end-stage lung disease, these recipients may be at a disadvantage overall when compared with DLT recipients in developing complicated Aspergillus infections. Whether em pirical therapy with antifungal agents can be of benefit to SLT patients in reducing this morbidity from Aspergillus infection needs to be further investigated.
